It was a bad night for MAHA candidates. And fierce opponents to RFK Jr. won seats in Congress. More: wsj.com/livecoverage/midterm…

NEW—How Haley Stevens turned from team player to party pariah. - Stevens privately signaled her skepticism of the race just weeks after she lost to Abdul El-Sayed in the primaries - After a recent publicized spat with El-Sayed, Democrats began speculating that she’d withdraw her endorsement - On Saturday, she sent out a flurry of text messages reassuring allies that she was still on team Abdul - That all changed Sunday morning—when she shocked her staff and party by endorsing GOP candidate Mike Rogers

Last night, STAT's Executive Editor Rick Berke accepted, in memory of Helen Branswell, the Kovler Prize for Trust in Life Science Journalism. Watch this video that Helen recorded in late summer to accept the award. We miss you, Helen. piped.video/watch?v=Rsu5Zr8I…

@MHackman is one of the coolest people I know, and in this amazing video she takes you to her Persian Jewish community to explore the complicated politics of the ongoing war in Iran. Definitely worth watching: wsj.com/video/series/rooted-…

ICYMI: Health Secretary Robert F. Kennedy Jr. is temporarily allowing six unapproved peptides on the market, despite warnings from government scientists that there isn’t enough evidence to prove they are safe or effective. wsj.com/health/healthcare/rf…

A 3-year-old was woken minutes into a nap to get more autism therapy. Was it good treatment or “simple business math”? wsj.com/health/healthcare/au… via @WSJ

To the scientific world, Moderna’s cancer vaccine’s results proved that a highly personalized, immune-targeting medication can work. To investors, it didn’t work well enough. W/ @xavierjohnm: wsj.com/health/pharma/modern…

A wild October surprise. w/ @LizzyLaw_

EXCLUSIVE - Top RFK Jr. ally and adviser Calley Means has quit the Trump administration. Means was frustrated by White House delays of some of Kennedy’s popular food policies and blamed others in the administration for allowing food companies and special interests to have too much sway, people familiar with the matter said. One of them described him as “disillusioned.” wsj.com/politics/policy/call…

NEW: I dug into a new class of drugs called "protein degraders" that pharma companies are pouring billions of dollars into, hoping to find a new tool to attack diseases from cancer to Parkinson’s. wsj.com/health/pharma/big-ph…

Helen was such an inspiration to me and to every young reporter in STAT's newsroom. Feel so lucky to have seen her genius, her fierceness, her kindness up close. A moving obit from @DrewQJoseph: statnews.com/2026/10/13/hele…

Helen Branswell was a gift — to family and friends, to colleagues, and to masses of people whose lives were made better by the work to which she was so devoted. I was lucky to know her. statnews.com/2026/10/13/hele…

Thank you to the Loeb Awards for this honor, and to @ZTracer, @rickberke, and my colleagues @statnews for shepherding my coverage of the FDA last year

Huge congratulations to @LizzyLaw_ @statnews’ third Loeb award in a row, and fourth in our history

In Ohio, a trucker tries to make sense of the moment when Pierre Damas Bel, a Haitian immigrant, stepped in front of his path. “I keep on thinking about it,” Jack Buhring told @mccrummens: theatlantic.com/politics/202…

Tennessee's failed execution of Christa Pike has resulted in fresh scrutiny of the shaky and secretive supply chain for lethal injection drugs. W/ @AlexLJanin: wsj.com/health/pharma/botche…

ICYMI: The Trump administration is rolling out a program aimed at getting Medicare to match prices in other countries for certain high-cost drugs, such as cancer and autoimmune disorder medicines. W/ @l_e_whyte wsj.com/health/pharma/trump-…

NEW with @LizzyLaw_: The Trump administration is rolling out a program aimed at getting Medicare to match drug prices in other countries for certain high-cost drugs Pharma companies that cut deals with the admin expected to be exempt wsj.com/health/pharma/trump-…

SCOOP with @ByKLong @ceostroff: - The CFTC is examining unusual Kalshi trades with near-identical sizes that now total over $5B - Prop-trading firms Jump Trading (a Kalshi shareholder) and Wintermute were two of the parties involved in the transactions We analyzed months of Kalshi data. The trades, all clustered near $5,500, began in late August (see chart).

NEW: Pharmaceutical Companies Push Trump Administration to Protect China Deals wsj.com/health/pharma/pharma…